Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in ras-transformed breast epithelial cells

Neoplasia

Volumn 10, Issue 12, 2008, Pages 1444-1458

  Li, Quanwen ^a   Mattingly, Raymond R ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN LIGHT CHAIN KINASE; RAC PROTEIN; RAS PROTEIN; UVOMORULIN;

ARTICLE; BREAST EPITHELIUM; CELL JUNCTION; CELL STRUCTURE; CELL SURFACE; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME INHIBITION; EPITHELIUM CELL; GENE ACTIVATION; HUMAN; HUMAN CELL; MESENCHYME; ONCOGENE H RAS; ONCOGENE N RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 57349178376     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08968     Document Type: Article

References (69)

1. Knudsen KA and Wheelock MJ (2005). Cadherins and the mammary gland. J Cell Biochem 95, 488-496.
2. Cowin P, Rowlands TM, and Hatsell SJ (2005). Cadherins and catenins in breast cancer. Curr Opin Cell Biol 17, 499-508.
3. Gottardi CJ, Wong E, and Gumbiner BM (2001). E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol 153, 1049-1060.
4. Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, et al. (2007). Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 44, 726-731.
5. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, et al. (2008). Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14, 1938-1946.
6. Thompson EW, Torri J, Sabol M, Sommers CL, Byers S, Valverius EM, Martin GR, Lippman ME, Stampfer MR, and Dickson RB (1994). Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis 12, 181-194.
7. Hajra KM, Chen DY, and Fearon ER (2002). The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 62, 1613-1618.
8. Hajra KM, Ji X, and Fearon ER (1999). Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 18, 7274-7279.
9. Schmidt CR, Washington MK, Gi YJ, Coffey RJ, Beauchamp RD, and Pearson AS (2003). Dysregulation of E-cadherin by oncogenic Ras in intestinal epithelial cells is blocked by inhibiting MAP kinase. Am J Surg 186, 426-430.
10. Sauer T, Boudjema G, Jebsen PW, and Naess O (2001). Immunocytochemical expression of E-cadherin on fine-needle aspirates from breast carcinomas correlate with the cell dissociation pattern seen on smears. Diagn Cytopathol 25, 382-388.
11. Yap AS, Crampton MS, and Hardin J (2007). Making and breaking contacts: the cellular biology of cadherin regulation. Curr Opin Cell Biol 19, 508-514.
12. Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, and Roche J (2005). Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia 7, 180-189.
13. Bryant DM and Stow JL (2004). The ins and outs of E-cadherin trafficking. Trends Cell Biol 14, 427-434.
14. Zhong C, Kinch MS, and Burridge K (1997). Rho-stimulated contractility contributes to the fibroblastic phenotype of Ras-transformed epithelial cells. Mol Biol Cell 8, 2329-2344.
15. Braga VM, Machesky LM, Hall A, and Hotchin NA (1997). The small GTPases Rho and Rac are required for the establishment of cadherin-dependent cell-cell contacts. J Cell Biol 137, 1421-1431.
16. Wojciak-Stothard B, Entwistle A, Garg R, and Ridley AJ (1998). Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J Cell Physiol 176, 150-165.
17. Wang B, Wylie FG, Teasdale RD, and Stow JL (2005). Polarized trafficking of E-cadherin is regulated by Rac1 and Cdc42 in Madin-Darby canine kidney cells. Am J Physiol Cell Physiol 288, C1411-C1419.
18. Avizienyte E, Fincham VJ, Brunton VG, and Frame MC (2004). Src SH3/2 domain-mediated peripheral accumulation of Src and phospho-myosin is linked to deregulation of E-cadherin and the epithelial-mesenchymal transition. Mol Biol Cell 15, 2794-2803.
19. Qian X, Karpova T, Sheppard AM, McNally J, and Lowy DR (2004). E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 23, 1739-1748.
20. Bremm A, Walch A, Fuchs M, Mages J, Duyster J, Keller G, Hermannstadter C, Becker KF, Rauser S, Langer R, et al. (2008). Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations. Cancer Res 68, 707-714.
21. Hazan RB and Norton L (1998). The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem 273, 9078-9084.
22. Hoschuetzky H, Aberle H, and Kemler R (1994). Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 127, 1375-1380.
23. Nam JS, Ino Y, Sakamoto M, and Hirohashi S (2002). Ras farnesylation inhibitor FTI-277 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Jpn J Cancer Res 93, 1020-1028.
24. Ray RM, Vaidya RJ, and Johnson LR (2007). MEK/ERK regulates adherens junctions and migration through Rac1. Cell Motil Cytoskeleton 64, 143-156.
25. Zondag GC, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, and Collard JG (2000). Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol 149, 775-782.
26. Schmidt CR, Gi YJ, Patel TA, Coffey RJ, Beauchamp RD, and Pearson AS (2005). E-cadherin is regulated by the transcriptional repressor SLUG during Ras-mediated transformation of intestinal epithelial cells. Surgery 138, 306-312.
27. Schmidt CR, Gi YJ, Coffey RJ, Beauchamp RD, and Pearson AS (2004). Oncogenic Ras dominates overexpression of E-cadherin in malignant transformation of intestinal epithelial cells. Surgery 136, 303-309.
28. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, and Boss GR (2000). Ras activation in human breast cancer. Breast Cancer Res Treat 62, 51-62.
29. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, and van Roy F (1991). Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66, 107-119.
30. Moon A, Kim MS, Kim TG, Kim SH, Kim HE, Chen YQ, and Kim HR (2000). H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: a role for MMP-2 in the H-ras-induced invasive phenotype. Int J Cancer 85, 176-181.
31. Li Q, Mullins SR, Sloane BF, and Mattingly RR (2008). p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. Neoplasia 10, 314-329.
32. Ireton RC, Davis MA, van Hengel J, Mariner DJ, Barnes K, Thoreson MA, Anastasiadis PZ, Matrisian L, Bundy LM, Sealy L, et al. (2002). A novel role for p120 catenin in E-cadherin function. J Cell Biol 159, 465-476.
33. Mattingly RR, Kraniak JM, Dilworth JT, Mathieu P, Bealmear B, Nowak JE, Benjamins JA, Tainsky MA, and Reiners JJ Jr (2006). The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. J Pharmacol Exp Ther 316, 456-465.
34. Yang H and Mattingly RR (2006). The Ras-GRF1 exchange factor coordinates activation of H-Ras and Rac1 to control neuronal morphology. Mol Biol Cell 17, 2177-2189.
35. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, and Brooks SC (1990). Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50, 6075-6086.
36. Menard RE, Jovanovski AP, and Mattingly RR (2005). Active p21-activated kinase 1 rescues MCF10A breast epithelial cells from undergoing anoikis. Neoplasia 7, 638-645.
37. Basolo F, Elliott J, Tait L, Chen XQ, Maloney T, Russo IH, Pauley R, Momiki S, Caamano J, Klein-Szanto AJ, et al. (1991). Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinog 4, 25-35.
38. Dawson PJ, Wolman SR, Tait L, Heppner GH, and Miller FR (1996). MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148, 313-319.
39. Eckert LB, Repasky GA, Ulku AS, McFall A, Zhou H, Sartor CI, and Der CJ (2004). Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 64, 4585-4592.
40. Li T and Sparano JA (2003). Inhibiting Ras signaling in the therapy of breast cancer. Clin Breast Cancer 3, 405-416discussion 417-420.
41. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357.
42. Miller FR, Santner SJ, Tait L, and Dawson PJ (2000). MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 92, 1185-1186.
43. Tanaka H, Shirkoohi R, Nakagawa K, Qiao H, Fujita H, Okada F, Hamada J, Kuzumaki S, Takimoto M, and Kuzumaki N (2006). siRNA gelsolin knockdown induces epithelial-mesenchymal transition with a cadherin switch in human mammary epithelial cells. Int J Cancer 118, 1680-1691.
44. Hazan RB, Qiao R, Keren R, Badano I, and Suyama K (2004). Cadherin switch in tumor progression. Ann N Y Acad Sci 1014, 155-163.
45. Ripple MO, Kalmadi S, and Eastman A (2005). Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival. Breast Cancer Res Treat 93, 177-188.
46. Liu YN, Lee WW, Wang CY, Chao TH, Chen Y, and Chen JH (2005). Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 24, 8277-8290.
47. Conacci-Sorrell M, Simcha I, Ben-Yedidia T, Blechman J, Savagner P, and Ben-Ze'ev A (2003). Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. J Cell Biol 163, 847-857.
48. Choi J, Park SY, and Joo CK (2007). Transforming growth factor-beta1 represses E-cadherin production via slug expression in lens epithelial cells. Invest Ophthalmol Vis Sci 48, 2708-2718.
49. Malliri A and Collard JG (2003). Role of Rho-family proteins in cell adhesion and cancer. Curr Opin Cell Biol 15, 583-589.
50. Evers EE, Zondag GC, Malliri A, Price LS, ten Klooster JP, van der Kammen RA, and Collard JG (2000). Rho family proteins in cell adhesion and cell migration. Eur J Cancer 36, 1269-1274.
51. O'Brien LE, Jou TS, Pollack AL, Zhang Q, Hansen SH, Yurchenco P, and Mostov KE (2001). Rac1 orientates epithelial apical polarity through effects on basolateral laminin assembly. Nat Cell Biol 3, 831-838.
52. Yu W, Datta A, Leroy P, O'Brien LE, Mak G, Jou TS, Matlin KS, Mostov KE, and Zegers MM (2005). Beta1-integrin orients epithelial polarity via Rac1 and laminin. Mol Biol Cell 16, 433-445.
53. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, and Nieto MA (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2, 76-83.
54. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, and van Roy F (2001). The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 7, 1267-1278.
55. Vesuna F, van Diest P, Chen JH, and Raman V (2008). Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun 367, 235-241.
56. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N, Beug H, and Wirth T (2004). NF-kappaB is essential for epithelial- mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114, 569-581.
57. Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW, Turley EA, and Bissell MJ (2002). Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst 94, 1494-1503.
58. Ward KR, Zhang KX, Somasiri AM, Roskelley CD, and Schrader JW (2004). Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and tumorigenesis. Oncogene 23, 1187-1196.
59. Brissette JL, Missero C, Yuspa SH, and Dotto GP (1993). Different levels of v-Ha-ras p21 expression in primary keratinocytes transformed with Harvey sarcoma virus correlate with benign versus malignant behavior. Mol Carcinog 7, 21-25.
60. Kfir S, Ehrlich M, Goldshmid A, Liu X, Kloog Y, and Henis YI (2005). Pathwayand expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling. Mol Cell Biol 25, 8239-8250.
61. Vial E, Sahai E, and Marshall CJ (2003). ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4, 67-79.
62. Jiang K, Delarue FL, and Sebti SM (2004). EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene 23, 1136-1145.
63. Gu LZ, Hu WY, Antic N, Mehta R, Turner JR, and de Lanerolle P (2006). Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells. Eur J Cancer 42, 948-957.
64. Takaishi K, Sasaki T, Kotani H, Nishioka H, and Takai Y (1997). Regulation of cell-cell adhesion by rac and rho small G proteins in MDCK cells. J Cell Biol 139, 1047-1059.
65. Hordijk PL, ten Klooster JP, van der Kammen RA, Michiels F, Oomen LC, and Collard JG (1997). Inhibition of invasion of epithelial cells by Tiam1-Rac signaling. Science 278, 1464-1466.
66. Liu AX, Rane N, Liu JP, and Prendergast GC (2001). RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol Cell Biol 21, 6906-6912.
67. Mattingly RR, Gibbs RA, Menard RE, and Reiners JJ Jr (2002). Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase. J Pharmacol Exp Ther 303, 74-81.
68. Saha B, Chaiwun B, Imam SS, Tsao-Wei DD, Groshen S, Naritoku WY, and Imam SA (2007). Overexpression of E-cadherin protein in metastatic breast cancer cells in bone. Anticancer Res 27, 3903-3908.
69. Allen LF, Sebolt-Leopold J, and Meyer MB (2003). CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30, 105-116.